Effects of herbal products on the metabolism and transport of anticancer agents

Bibliography

• Gatenby RA. A change of strategy in the war on cancer. Nature 2009;459:508-9
   PubMed Web of Science ®Google Scholar
• Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005;12:243-53
   PubMedGoogle Scholar
• Pierotti MA, Negri T, Tamborini E, Targeted therapies: the rare cancer paradigm. Mol Oncol 2010;4:19-37
   PubMed Web of Science ®Google Scholar
• Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005;5:65-72
   PubMed Web of Science ®Google Scholar
• Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5:447-58
   PubMed Web of Science ®Google Scholar
• Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol 2005;6:780-9
   PubMed Web of Science ®Google Scholar
• Kamb A, Wee S, Lengauer C. Why is cancer drug discovery so difficult? Nat Rev Drug Discov 2007;6:115-20
   PubMed Web of Science ®Google Scholar
• Yague E, Raguz S. Drug resistance in cancer. Br J Cancer 2005;93:973-6
   PubMed Web of Science ®Google Scholar
• Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther 2009;8:29-36
   PubMed Web of Science ®Google Scholar
• Ernst E, Cassileth BR. The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer 1998;83:777-82
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Cox MC, Acharya MR, Figg WD. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 2004;22:2489-503
   PubMed Web of Science ®Google Scholar
• McCune JS, Hatfield AJ, Blackburn AA, Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer 2004;12:454-62
   PubMed Web of Science ®Google Scholar
• Warshafsky S, Kamer RS, Sivak SL. Effect of garlic on total serum cholesterol. A meta-analysis. Ann Intern Med 1993;119:599-605
   PubMed Web of Science ®Google Scholar
• Werneke U, Earl J, Seydel C, Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 2004;90:408-13
   PubMed Web of Science ®Google Scholar
• MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002;35:166-73
   PubMed Web of Science ®Google Scholar
• Engdal S, Steinsbekk A, Klepp O, Nilsen OG. Herbal use among cancer patients during palliative or curative chemotherapy treatment in Norway. Support Care Cancer 2008;16:763-9
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang X, Ho PC, Herb–drug interactions: a literature review. Drugs 2005;65:1239-82
   PubMed Web of Science ®Google Scholar
• Meijerman I, Beijnen JH, Schellens JH. Herb–drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006;11:742-52
   PubMed Web of Science ®Google Scholar
• Yang AK, He SM, Liu L, Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Curr Med Chem 2010;17:1635-78
   PubMed Web of Science ®Google Scholar
• Shord SS, Shah K, Lukose A. Drug–botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther 2009;8:208-27
   PubMed Web of Science ®Google Scholar
• Williamson E. Stockley's herbal medicines interactions. Pharmaceutical Press, London; 2009
   Google Scholar
• Yeung KS, Gubili J. Clinical guide to herb–drug interactions in oncology. J Soc Integr Oncol 2007;5:113-17
   PubMedGoogle Scholar
• Lee CO. Herbs and cytotoxic drugs: recognizing and communicating potentially relevant interactions. Clin J Oncol Nurs 2005;9:481-7
   PubMedGoogle Scholar
• Chiu J, Yau T, Epstein RJ. Complications of traditional Chinese/herbal medicines (TCM) – a guide for perplexed oncologists and other cancer caregivers. Support Care Cancer 2009;17:231-40
   PubMed Web of Science ®Google Scholar
• Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006;6:546-58
   PubMed Web of Science ®Google Scholar
• Gratus C, Wilson S, Greenfield SM, The use of herbal medicines by people with cancer: a qualitative study. BMC Complement Altern Med 2009;9:14
   PubMedGoogle Scholar
• Girgis A, Adams J, Sibbritt D. The use of complementary and alternative therapies by patients with cancer. Oncol Res 2005;15:281-9
   PubMed Web of Science ®Google Scholar
• Memorial Sloan-Kettering Cancer Center. Available from: http://www.mskcc.org/mskcc/html/11570.cfm. July 2010
   Google Scholar
• Block KI, Gyllenhaal C, Mead MN. Safety and efficacy of herbal sedatives in cancer care. Integr Cancer Ther 2004;3:128-48
   PubMedGoogle Scholar
• Ho JW, Leung YK, Chan CP. Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents 2002;2:209-14
   PubMedGoogle Scholar
• Vickers A. Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. Cancer Invest 2002;20:1069-79
   PubMed Web of Science ®Google Scholar
• Mok T, Yeo W, Johnson P, A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity. Ann Oncol 2007;18:768-74
   PubMed Web of Science ®Google Scholar
• Boon H, Wong J. Botanical medicine and cancer: a review of the safety and efficacy. Expert Opin Pharmacother 2004;5:2485-501
   PubMed Web of Science ®Google Scholar
• Ernst E. The role of complementary and alternative medicine in cancer. Lancet Oncol 2000;1:176-80
   PubMedGoogle Scholar
• Rooseboom M, Commandeur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56:53-102
   PubMed Web of Science ®Google Scholar
• Zhou S, Gao Y, Jiang W, Interactions of herbs with cytochrome P450. Drug Metab Rev 2003;35:35-98
   PubMed Web of Science ®Google Scholar
• Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-66
   PubMed Web of Science ®Google Scholar
• Tian Q, Zhang J, Chan SY, Topotecan is a substrate for multidrug resistance associated protein 4. Curr Drug Metab 2006;7:105-18
   PubMed Web of Science ®Google Scholar
• Noguchi K, Katayama K, Mitsuhashi J, Sugimoto Y. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev 2009;61:26-33
   PubMed Web of Science ®Google Scholar
• Cui Y, Konig J, Buchholz JK, Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999;55:929-37
   PubMed Web of Science ®Google Scholar
• Kool M, van der Linden M, de Haas M, MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 1999;96:6914-19
   PubMed Web of Science ®Google Scholar
• Chen ZS, Lee K, Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001;276:33747-54
   PubMed Web of Science ®Google Scholar
• Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000;275:30069-74
   PubMed Web of Science ®Google Scholar
• Oguri T, Bessho Y, Achiwa H, MRP8/ABCC11 directly confers resistance to 5-fluorouracil. Mol Cancer Ther 2007;6:122-7
   PubMed Web of Science ®Google Scholar
• Haber M, Smith J, Bordow SB, Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J Clin Oncol 2006;24:1546-53
   PubMed Web of Science ®Google Scholar
• Hulot JS, Villard E, Maguy A, A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005;15:277-85
   PubMed Web of Science ®Google Scholar
• Innocenti F, Undevia SD, Iyer L, Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004;22:1382-8
   PubMed Web of Science ®Google Scholar
• Plasschaert SL, de Bont ES, Boezen M, Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin Cancer Res 2005;11:8661-8
   PubMed Web of Science ®Google Scholar
• Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 2003;52:1788-95
   PubMed Web of Science ®Google Scholar
• Zhou SF, Wang LL, Di YM, Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008;15:1981-2039
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Verweij J, de Bruijn P, Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002;94:1247-9
   PubMed Web of Science ®Google Scholar
• Humerickhouse R, Lohrbach K, Li L, Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000;60:1189-92
   PubMed Web of Science ®Google Scholar
• Mathijssen RHJ, van Alphen RJ, Verweij J, Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94
   PubMed Web of Science ®Google Scholar
• Chu XY, Kato Y, Niinuma K, Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997;281:304-14
   PubMed Web of Science ®Google Scholar
• Santos A, Zanetta S, Cresteil T, Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000;6:2012-20
   PubMed Web of Science ®Google Scholar
• Kehrer DF, Yamamoto W, Verweij J, Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res 2000;6:3451-8
   PubMed Web of Science ®Google Scholar
• van Erp NP, Baker SD, Zhao M, Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005;11:7800-6
   PubMed Web of Science ®Google Scholar
• Wen Z, Dumas TE, Schrieber SJ, Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008;36:65-72
   PubMed Web of Science ®Google Scholar
• Johnson JR, Bross P, Cohen M, Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003;9:1972-9
   PubMed Web of Science ®Google Scholar
• Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-19
   PubMed Web of Science ®Google Scholar
• Dutreix C, Peng B, Mehring G, Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-4
   PubMed Web of Science ®Google Scholar
• Wolf D, Rumpold H. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Saf 2009;32:1001-15
   PubMed Web of Science ®Google Scholar
• Gschwind HP, Pfaar U, Waldmeier F, Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-12
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Karlsson MO, Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007;13:7394-400
   PubMed Web of Science ®Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF, Effect of St. John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004;76:323-9
   PubMed Web of Science ®Google Scholar
• Smith P, Bullock JM, Booker BM, The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004;24:1508-14
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-9
   PubMed Web of Science ®Google Scholar
• Fulton B, Spencer CM. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer. Drugs 1996;51:1075-92
   PubMed Web of Science ®Google Scholar
• Saloustros E, Mavroudis D, Georgoulias V. Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin Pharmacother 2008;9:2603-16
   PubMed Web of Science ®Google Scholar
• Cox MC, Low J, Lee J, Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006;12:4636-40
   PubMed Web of Science ®Google Scholar
• Marre F, Sanderink GJ, de Sousa G, Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56:1296-302
   PubMed Web of Science ®Google Scholar
• Hu ZP, Yang XX, Chen X, A mechanistic study on altered pharmacokinetics of irinotecan by St. John's wort. Curr Drug Metab 2007;8:157-71
   PubMed Web of Science ®Google Scholar
• Hu Z, Yang X, Ho PC, St. John's wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005;22:902-14
   PubMed Web of Science ®Google Scholar
• Hu ZP, Yang XX, Chan SY, St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006;216:225-37
   PubMed Web of Science ®Google Scholar
• Linde K, Mulrow CD, Berner M, Egger M. St. John's wort for depression. Cochrane Database Syst Rev 2005:CD000448
   Google Scholar
• Moore LB, Goodwin B, Jones SA, St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500-2
   PubMed Web of Science ®Google Scholar
• Goodwin B, Moore LB, Stoltz CM, Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001;60:427-31
   PubMed Web of Science ®Google Scholar
• Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Curr Drug Metab 2008;9:394-409
   PubMed Web of Science ®Google Scholar
• Orans J, Teotico DG, Redinbo MR. The nuclear xenobiotic receptor pregnane X receptor: recent insights and new challenges. Mol Endocrinol 2005;19:2891-900
   PubMed Web of Science ®Google Scholar
• Hennessy M, Kelleher D, Spiers JP, St. John's wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002;53:75-82
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Stormer E, Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134:1601-8
   PubMed Web of Science ®Google Scholar
• Durr D, Stieger B, Kullak-Ublick GA, St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598-604
   PubMed Web of Science ®Google Scholar
• Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St. John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50
   PubMed Web of Science ®Google Scholar
• Xie R, Tan LH, Polasek EC, CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005;45:352-6
   PubMed Web of Science ®Google Scholar
• Wang ZQ, Hamman MA, Huang SM, Effect of St. John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-20
   PubMed Web of Science ®Google Scholar
• Bauer S, Stormer E, Johne A, Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St. John's wort in renal transplant patients. Br J Clin Pharmacol 2003;55:203-11
   PubMed Web of Science ®Google Scholar
• Hamada A, Miyano H, Watanabe H, Saito H. Interaction of imatinib mesilate with human P-glycoprotein. J Pharmacol Exp Ther 2003;307:824-8
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C, Hegedus T, Varady G, High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol Pharmacol 2004;65:1485-95
   PubMed Web of Science ®Google Scholar
• Hu S, Franke RM, Filipski KK, Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008;14:3141-8
   PubMed Web of Science ®Google Scholar
• Oostendorp RL, Buckle T, Beijnen JH, The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib. Invest New Drugs 2009;27:31-40
   PubMed Web of Science ®Google Scholar
• Lehmann JM, McKee DD, Watson MA, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23
   PubMed Web of Science ®Google Scholar
• Di YM, Li CG, Xue CC, Zhou SF. Clinical drugs that interact with St. John's wort and implication in drug development. Curr Pharm Des 2008;14:1723-42
   PubMed Web of Science ®Google Scholar
• Zhou S, Chan E, Pan SQ, Pharmacokinetic interactions of drugs with St. John's wort. J Psychopharmacol 2004;18:262-76
   PubMed Web of Science ®Google Scholar
• Zhou S, Yung Chan S, Cher Goh B, Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005;44:279-304
   PubMed Web of Science ®Google Scholar
• Alvarez AI, Real R, Perez M, Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. J Pharm Sci 2010;99:598-617
   PubMed Web of Science ®Google Scholar
• Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004;36:57-104
   PubMed Web of Science ®Google Scholar
• Zhou SF, Zhou ZW, Li CG, Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007;12:664-73
   PubMed Web of Science ®Google Scholar
• Volak LP, Court MH. Role for protein kinase C delta in the functional activity of human UGT1A6: implications for drug–drug interactions between PKC inhibitors and UGT1A6. Xenobiotica 2010;40:306-18
   PubMed Web of Science ®Google Scholar
• Wu JW, Lin LC, Tsai TH. Drug–drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009;121:185-93
   PubMed Web of Science ®Google Scholar
• Okura T, Ibe M, Umegaki K, Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 2010;33:255-9
   PubMed Web of Science ®Google Scholar
• Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005;327:866-70
   PubMed Web of Science ®Google Scholar
• Engdal S, Nilsen OG. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008;38:559-73
   PubMed Web of Science ®Google Scholar
• Zhang W, Lim LY. Effects of spice constituents on P-glycoprotein-mediated transport and CYP3A4-mediated metabolism in vitro. Drug Metab Dispos 2008;36:1283-90
   PubMed Web of Science ®Google Scholar
• Berginc K, Zakelj S, Ursic D, Kristl A. Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull 2009;32:694-9
   PubMed Web of Science ®Google Scholar
• Choi CH, Kang G, Min YD. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 2003;69:235-40
   PubMed Web of Science ®Google Scholar
• Wortelboer HM, Usta M, van Zanden JJ, Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha,beta-unsaturated carbonyl compounds. Biochem Pharmacol 2005;69:1879-90
   PubMed Web of Science ®Google Scholar
• Jin J, Shahi S, Kang HK, Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006;345:1308-14
   PubMed Web of Science ®Google Scholar
• Ebert B, Seidel A, Lampen A. Phytochemicals induce breast cancer resistance protein in Caco-2 cells and enhance the transport of benzo[a]pyrene-3-sulfate. Toxicol Sci 2007;96:227-36
   PubMed Web of Science ®Google Scholar
• Tamaki H, Satoh H, Hori S, Inhibitory effects of herbal extracts on breast cancer resistance protein (BCRP) and structure–inhibitory potency relationship of isoflavonoids. Drug Metab Pharmacokinet 2010;25:170-9
   PubMed Web of Science ®Google Scholar
• Huang Y, Anderle P, Bussey KJ, Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 2004;64:4294-301
   PubMed Web of Science ®Google Scholar